SCOPE: Strategies to Combine PrEP With Prevention Efforts (SCOPE)
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Open Label Prospective Study of Strategies to Combine Pre-Exposure Prophylaxis (PrEP)With Prevention Efforts|
- Drug Adherence [ Time Frame: 11 months ]Describe the patterns of adherence to a regimen of daily oral Truvada® among female sex workers currently or newly enrolled in established HIV prevention programs
- PrEP Integration [ Time Frame: 11 months ]Assess the feasibility of integrating PrEP into existing HIV prevention programs for female sex workers
- Assess adherence [ Time Frame: 11 months ]Describe self-reported and electronically-monitored patterns of adherence to a regimen of daily oral Truvada® among female sex workers currently or newly enrolled in established HIV prevention programs
- drug level adherence [ Time Frame: 11 months ]Assess the correlation between drug level adherence data and participant self-reported adherence data
- risk-taking behavior [ Time Frame: 11 months ]Assess the impact of PrEP on HIV risk-taking behavior
- factors affecting Adherence [ Time Frame: 11 months ]Identify factors associated with adherence to PrEP
- Support of prEP Adherence [ Time Frame: 11 months ]Assess impact of adherence support by peer educators on PrEP adherence
- Contraceptive Use [ Time Frame: 11 months ]Describe Contraceptive Use
- Resistance among Seroconverters [ Time Frame: 11 months ]Assess resistance to TFV or FTC among seroconverters
- Birth Outcomes [ Time Frame: 11 months ]Assess birth outcomes among women who choose to continue PrEP during pregnancy
- Tenofovir Concentrations [ Time Frame: 11 months ]9. Describe tenofovir concentrations among women who choose to continue PrEP during pregnancy
|Study Start Date:||June 2013|
|Study Completion Date:||July 2013|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Experimental: Once daily Truvada®
One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
Drug: Once daily Truvada®
At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
Other Name: Truvada®
Participants will undergo the following procedures: blood draw for HIV (screening, enrollment, month 1, quarterly follow-up visits and final) and creatinine testing (screening, month 3 and final) and urine pregnancy test (at screening, enrollment and final). At screening, participants will have an HBV antigen test. Information on demographics, sexual behaviors, risk perceptions, partners' HIV status, medical history, PrEP and program acceptability, self-reported adherence to PrEP, alcohol and drug use, depression, social support, stigma, self-efficacy, gender-based violence, contraceptive use, adverse events, and symptoms of potential acute HIV infection will be collected during the study. Detailed information on Truvada for PrEP will be given to the participant and the the participant will be counseled on HIV-risk reduction (according to existing program) during the screening visit. Patient-centered and integrated counseling on HIV risk reduction and PrEP adherence will be conducted at enrollment and follow-up visits. Sexually transmitted infections (STI)will be assessed and treated during visits per local clinical procedures. If a pelvic exam is done per routine clinic procedures, a vaginal and/or endocervical swab will be collected and stored for future research related to HIV infection.
A cohort of 25 systematically-selected participants at each site will have three rounds of in-depth interviews (IDI) to explore the context surrounding many of the study's endpoints. The first IDI will be conducted at the month 1 visit after PrEP initiation. The second IDI will be conducted at the month 3 visit. The third IDI will be conducted at the final study visit.
An IDI will be conducted with all participants at each site who were assigned and willing to use the electronic pill monitoring device (n=25 per site). The purpose of the IDIs is to explore the reasons underlying PrEP use patterns (e.g. the number of times the pill bottle was opened over a specific period of time -- limited, intermittent, or high number of openings). Two rounds of IDIs will be conducted with these participants. The first IDI will be conducted at the month 3 visit and the second at the month 6 visit.
Exit interviews will be conducted with up to 30 participants at each site. Participants may be purposefully selected based on their drug level adherence data or electronic pill measurement data (e.g. low, intermittent, or high PrEP users) or based on other specific issues that emerged over the course of the study (e.g., limited partner support).
Two brief face-to-face (FTF) structured surveys will be administered to all HIV prevention program staff to assess the variables/domains related to the feasibility measures. The first survey will be administered around the initiation of the study and the second survey towards the end of the study. Two interviews will be conducted using a questionnaire with both open- and closed-ended questions, with all counselors and providers, such as nurses, medical officers, and doctors, to gather more in-depth data on the feasibility measures. The first interview will be conducted approximately one month after the first participant is screened and the second interview toward the end of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01832571
|Family Health Options Kenya|
|Sex Workers Outreach Programme (SWOP)|
|Principal Investigator:||Jennifer Deese, MPH||FHI 360|
|Principal Investigator:||Amy Corneli, Ph.D.||FHI 360|